AG真人官方

Medicus Pharma Ltd. (NASDAQ: MDCX) filed an amended Form 8-K (8-K/A) dated June 29, 2025 to include Exhibit 2.1鈥攊ts Share Exchange Agreement with Antev Limited and certain Antev security-holders. The amendment fulfils a disclosure commitment made in the original 8-K filed June 30, 2025 and does not modify any other information previously reported.

The Share Exchange Agreement outlines the terms of a proposed transaction whereby Medicus would acquire Antev, the developer of prostate-cancer candidate Teverelix. While the full exhibit is now filed (with certain portions redacted under Reg S-K 601), the 8-K/A contains no new financial results, purchase price figures or closing timelines.

Other exhibits are unchanged: (i) Exhibit 99.1 (June 30 press release) is incorporated by reference, and (ii) Exhibit 104 provides inline XBRL for the cover page. Standard forward-looking statement language cautions investors about completion risk, clinical development uncertainty and other factors referenced in the company鈥檚 2024 Annual Report.

Key takeaways for investors:

• The filing is largely administrative鈥攊ts sole purpose is to publicly attach the Share Exchange Agreement promised in the earlier 8-K.
• No valuation metrics, consideration mix, or closing conditions are disclosed in this amendment; investors must review the newly filed exhibit for details.
• The proposed acquisition could expand Medicus鈥檚 oncology pipeline if consummated, but the 8-K/A itself provides no update on timing or probability.

Medicus Pharma Ltd. (NASDAQ: MDCX) has filed Offering Circular Supplement No. 8 under Rule 253(g)(2), updating its April 10, 2025 Offering Circular. The filing attaches the company鈥檚 June 30, 2025 Current Report, which discloses a definitive agreement to acquire Antev Ltd., a clinical-stage biotech developing the GnRH antagonist Teverelix for prostate-related indications.

Transaction terms: Medicus will issue 2,666,600 new common shares (鈮� 17 % of pro-forma shares outstanding) to Antev securityholders. Shares will be subject to a 36-month staggered lock-up and voting proxy in favour of Medicus management. Antev holders may receive up to US$65 million in milestone payments tied to future FDA Phase 2 and NDA approvals. Closing is targeted before end-August 2025, pending shareholder and regulatory consents.

Capital structure context: The company already has 1,490,000 common shares reserved for warrant exercises (strike $4.64, expiry Nov 15 2029). As of June 27 shares traded at $2.90 and public warrants at $0.95. The filing reiterates Medicus鈥� 鈥渆merging growth company鈥� status and directs investors to existing risk disclosures.

Strategic rationale: The acquisition adds a late-preclinical/early-clinical asset targeting sizable prostate-cancer and BPH markets. Management highlights potential first-in-class positioning and cardiovascular safety advantages. However, the deal entails immediate dilution and substantial contingent consideration, and its completion is uncertain.

Medicus Pharma has filed a 253G2 offering circular supplement announcing key executive changes and warrant details. The company is offering 1,490,000 common shares issuable upon warrant exercise, with Public Warrants having an exercise price of $4.64 and expiration date of November 15, 2029.

Key highlights:

• Appointed Andrew Smith (57) as Chief Operating Officer, effective June 30, 2025
• Smith brings 30+ years experience in asset management and financial operations
• Employment package includes $325,000 annual base salary and 100,000 stock options at $2.60 strike price, vesting quarterly over 5 years
• Trading on Nasdaq Capital Market under symbols MDCX (shares) and MDCXW (warrants)
• Last reported share price: $2.49; warrant price: $0.80 (as of June 20, 2025)

The company maintains emerging growth company status, qualifying for reduced public company disclosure requirements.